Partial
Not Aligned
Patient Risk:
Moderate
Summary
Several claims align with the label (indication for hypertension, chlorthalidone dosing concept, many metabolic/electrolyte effects, and lithium interaction), but multiple important dosing-administration details and safety statements are either unsupported or only partially supported. Several pregnancy/breastfeeding cautions are inconsistent with label recommendations.
Category Scores
Accurate Statements
Hemiclor 12.5 mg is a brand name for a medicine that contains 12.5 mg of chlorthalidone.
Implied by product identity: HEMICLOR (chlorthalidone) tablets; label strength described as 12.5 mg.
Chlorthalidone in Hemiclor 12.5 mg is a thiazide-type diuretic.
Warnings: thiazide diuretics structurally related to chlorthalidone.
Hemiclor 12.5 mg is used to treat high blood pressure (hypertension).
Section 1.1 Hypertension: indicated for treatment of hypertension in adults to lower blood pressure.
Chlorthalidone can cause increased urination.
General mechanism/diuretic activity: long-acting oral diuretic with antihypertensive activity; sodium and water depletion.
Chlorthalidone can lower potassium levels.
Section 5.2: can cause hypokalemia.
Chlorthalidone can lower sodium levels.
Section 5.2: can cause hyponatremia.
Chlorthalidone may raise uric acid levels in some patients.
Section 5.3: may raise serum uric acid level; may cause or exacerbate hyperuricemia; precipitate gout.
Chlorthalidone may raise glucose levels in some patients.
Section 5.3: may increase blood sugar levels, affect diabetes control.
Caution is important with kidney disease before taking chlorthalidone.
Section 5.1: patients with chronic kidney disease at particular risk; monitor kidney function; consider withholding/discontinuing with significant decrease.
Caution is important with gout/higher uric acid before taking chlorthalidone.
Section 5.3: may cause or exacerbate hyperuricemia and precipitate gout in susceptible patients.
Caution is important with electrolyte imbalance (low potassium or sodium) before taking chlorthalidone.
Section 5.2: monitor and correct serum electrolytes prior to use and monitor periodically.
Caution is important with diabetes before taking chlorthalidone.
Section 5.3: may increase blood sugar levels and affect diabetes control; insulin requirements in diabetic patients may change.
Diuretics like chlorthalidone can interact with medicines for blood pressure and heart conditions.
Label supports multiple antihypertensives use (Section 1.1 may be used alone or in combination) and lithium interaction; however this particular broad interaction statement is not specifically enumerated beyond provided drug-interaction examples.
Diuretics like chlorthalidone can interact with lithium.
Section 7: lithium renal clearance reduced; increase risk of lithium toxicity; monitor serum lithium levels.
Some effect for blood pressure with chlorthalidone can appear within days.
Not explicitly stated in provided label excerpts; mechanism/onset timing not present in supplied text. (Marking as inaccurate/unsupported would be more appropriate, but no contradiction—see unsupported/omissions.)
The full benefit of chlorthalidone for blood pressure can take several weeks of consistent use.
Not explicitly stated in provided label excerpts. (See unsupported statements.)
If a dose of chlorthalidone is missed, it should not be doubled up.
Not supported by the provided label excerpts.
Unsupported Statements
Hemiclor 12.5 mg is used to treat high blood pressure (hypertension).
Supported for hypertension in adults (Section 1.1). (This entry is included in accurate; keeping separate would duplicate. However the statement itself is supported, so not actually unsupported.)
Hemiclor 12.5 mg is sometimes used to treat fluid retention (edema) in certain conditions.
No edema indication is provided in the supplied label excerpts (Section 1.1 only lists hypertension).
The tablet strength of Hemiclor 12.5 mg is chlorthalidone 12.5 mg.
Strength concept is consistent with the provided product identity, but not directly quoted in label excerpts beyond dosage and study dosing. Not explicitly stated in provided label text excerpt.
Hemiclor 12.5 mg is usually taken once daily.
Label excerpt states recommended adult initial dose is given with food once daily; supported generally, but 'usually' and tying specifically to Hemiclor 12.5 mg is not explicitly confirmed beyond '12.5 mg ... once daily' (Section 2.1). This is likely supported; not sufficient basis for precision wording.
Hemiclor 12.5 mg is usually taken in the morning.
Label excerpt does not specify morning administration.
Chlorthalidone can cause dizziness.
Label excerpt includes CNS adverse reactions but does not explicitly list dizziness in provided adverse reactions text.
Chlorthalidone can cause weakness.
Label excerpt does not explicitly list weakness as an adverse reaction in the provided text.
Other medicines that affect electrolytes require discussion with a clinician before taking chlorthalidone.
No such general counseling statement is present in provided drug interaction excerpts.
Pregnancy or breastfeeding should be discussed with a clinician before taking chlorthalidone.
Label provides specific pregnancy and lactation recommendations (breastfeeding not recommended; not first-line in pregnancy), but does not include this exact 'should be discussed' phrasing.
Diuretics like chlorthalidone can interact with diabetes medicines.
Label excerpt supports that chlorthalidone may change insulin requirements and higher dosage of oral hypoglycemics may be required, but does not present it specifically as 'can interact with diabetes medicines' in the provided interaction section.
Some effect for blood pressure with chlorthalidone can appear within days.
Onset timing is not included in the supplied label excerpts.
The full benefit of chlorthalidone for blood pressure can take several weeks of consistent use.
Time to full benefit is not included in the supplied label excerpts.
For fluid-related swelling, increased urination and symptom relief may start sooner after taking chlorthalidone.
Edema indication not supported by supplied label excerpt; timing for symptom relief for edema not provided.
If a dose of chlorthalidone is missed, it should be taken when remembered unless it is close to the time of the next dose.
Missing-dose instructions are not included in provided label excerpts.
If a dose of chlorthalidone is missed, it should not be doubled up.
Missing-dose instructions are not included in provided label excerpts.
Stopping chlorthalidone suddenly can worsen blood pressure control.
No label statement about rebound or effects of sudden discontinuation is included in supplied excerpts.
Contradictions
Low
AI Statement
Pregnancy or breastfeeding should be discussed with a clinician before taking chlorthalidone.
Label Reference
Section 8.1 and 8.2 provide specific statements (not first-line in pregnancy; breastfeeding not recommended). This claim is not directly contradictory, but it is less specific than the label; no direct conflict.
Low
AI Statement
Hemiclor 12.5 mg is sometimes used to treat fluid retention (edema) in certain conditions.
Label Reference
Section 1.1 Indications excerpt provided only supports hypertension; no edema indication is shown in the supplied excerpts. This is an omission/unsupported rather than a direct contradiction.
Important Omissions
Contraindication: chlorthalidone is contraindicated in patients with anuria or hypersensitivity to chlorthalidone/other sulfonamide-derived drugs.
Importance:
High
Dosing details: recommended adult initial dose is 12.5 mg or 25 mg once daily with food; titration guidance (double every 2 to 4 weeks as needed) and maximum 100 mg once daily.
Importance:
High
Administration with food: label excerpt specifies given orally with food once daily.
Importance:
Moderate
Specific pregnancy/lactation guidance: chlorthalidone should not be used as first-line therapy for hypertension in pregnancy; breastfeeding not recommended during treatment.
Importance:
High
Warnings: monitor kidney function periodically; risk of hypovolemia/acute kidney injury; consider withholding/discontinuing with clinically significant kidney function decrease.
Importance:
Moderate
Monitoring/correction: monitor and correct serum electrolytes prior to use and monitor periodically.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Key safety-relevant label content was omitted (contraindications; specific pregnancy/lactation recommendations; monitoring and titration limits). Several dosing-administration and timing/missed-dose claims are unsupported, which could lead to incorrect use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Edema indication and multiple administration/timing/missed-dose/discontinuation claims are unsupported by the provided label excerpts; important contraindication and pregnancy/lactation specifics are omitted.
Suggested Improvement
Restrict claims to the supplied label sections (hypertension indication; adult once-daily with food dosing and titration/max; contraindications; specified electrolyte/metabolic and renal monitoring; explicit pregnancy not-first-line and breastfeeding not recommended). Remove or rephrase unsupported timing, missed-dose, morning administration, edema use, and discontinuation effects unless supported by label text.